Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2019

Open Access 01-12-2019 | Ovarian Cancer | Primary research

Sevoflurane inhibits the progression of ovarian cancer through down-regulating stanniocalcin 1 (STC1)

Authors: Chuanfeng Zhang, Baosheng Wang, Xiuqin Wang, Xiugui Sheng, Yongchun Cui

Published in: Cancer Cell International | Issue 1/2019

Login to get access

Abstract

Background

Ovarian cancer is one of the leading causes of female death worldwide, with a poor prognosis of advanced patients. Sevoflurane, a volatile anesthetic commonly used in clinical operations, has been reported to have anti-cancer activity against some tumors. In the present study, we aimed to investigate the effects of sevoflurane on the progression of ovarian cancer and its potential mechanism.

Methods

The effects of sevoflurane on ovarian cancer cell viability, proliferation, migration, invasion, cell cycle, and apoptosis were determined by functional experiments in vitro. Gelatin zymography assay was performed to examine MMP9 activity. In vivo, sevoflurane was injected into mice of transplantation tumor with SKOV3 cells or with pcDNA-STC1 treated SKOV3 cells.

Results

We found that sevoflurane inhibited the viability of SKOV3 and OVCAR3 cells in a dose-dependent manner, and colony formation assay revealed that sevoflurane inhibited ovarian cancer cell colony-formation abilities. Additionally, sevoflurane could induce cell cycle arrest and promote cell apoptosis in SKOV3 and OVCAR3 cells. Moreover, sevoflurane reduced the migration and invasion abilities of SKOV3 and OVCAR3 cells, as well as the MMP-9 activity. Furthermore, sevoflurane down-regulated the expression of stanniocalcin 1 (STC1), and up-regulation of STC1 could reverse the inhibitory effects of sevoflurane on cell proliferation and invasion. In vivo, sevoflurane significantly inhibited the tumor growth, which was be reversed by STC1 overexpression.

Conclusion

These data reveal an anti-cancer activity of sevoflurane on the growth and invasion of ovarian cancer, which may be through down-regulating STC1. Sevoflurane may serve as a potential anti-cancer agent in ovarian cancer therapy.
Literature
1.
Szajnik M, Czystowskakuźmicz M, Elishaev E, Whiteside TL. Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma. Expert Rev Mol Diagn. 2016;16(8):1.CrossRef
2.
3.
Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385(9972):977–1010.PubMedCrossRef
4.
Torre LA, Trabert B, Desantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. Histopathology. 2018;68(4):284–96.
5.
Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018;81(1):17–38.PubMedCrossRef
6.
Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, Chauhan SC. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J Ovarian Res. 2010;3:11.PubMedPubMedCentralCrossRef
7.
Snyder GL, Greenberg S. Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth. 2010;105(2):106–15.PubMedCrossRef
8.
Chen X, Wu Q, You L, Chen S, Zhu M, Miao C. Propofol attenuates pancreatic cancer malignant potential via inhibition of NMDA receptor. Eur J Pharmacol. 2016;795:150–9.PubMedCrossRef
9.
Kvolik S, Glavas-Obrovac L, Bares V, Karner I. Effects of inhalation anesthetics halothane, sevoflurane, and isoflurane on human cell lines. Life Sci. 2005;77(19):2369–83.PubMedCrossRef
10.
Kvolik S, Dobrosevic B, Marczi S, Prlic L, Glavas-Obrovac L. Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2010;53(10):1192–9.
11.
Yang Y, Hu R, Yan J, Chen Z, Lu Y, Jiang J, Jiang H. Sevoflurane inhibits the malignant potential of head and neck squamous cell carcinoma via activating the hypoxia-inducible factor-1α signaling pathway in vitro. Int J Mol Med. 2018;41(2):995.PubMed
12.
Hua L, Gu M, Yang C, Wen X, Zhou Q. Sevoflurane inhibits invasion and migration of lung cancer cells by inactivating the p38 MAPK signaling pathway. J Anesth. 2012;26(3):381–92.CrossRef
13.
Hua L, Cheng XY, Zhang B, Zhen LZ, Ji YZ, Xian JW. Sevoflurane attenuates platelets activation of patients undergoing lung cancer surgery and suppresses platelets-induced invasion of lung cancer cells. J Clin Anesth. 2016;35:304–12.CrossRef
14.
Yi W, Li D, Guo Y, Zhang Y, Huang B, Li X. Sevoflurane inhibits the migration and invasion of glioma cells by upregulating microRNA-637. Int J Mol Med. 2016;38(6):1857.PubMedCrossRef
15.
Hurmath FK, Mittal M, Ramaswamy P, Umamaheswara Rao GS, Dalavaikodihalli NN. Sevoflurane and thiopental preconditioning attenuates the migration and activity of MMP-2 in U87MG glioma cells. Neurochem Int. 2016;94(2):32–8.PubMedCrossRef
16.
Zhang D, Zhou X-H, Zhang J, Zhou Y-X, Ying J, Wu G-Q, Qian J-H. Propofol promotes cell apoptosis via inhibiting HOTAIR mediated mTOR pathway in cervical cancer. Biochem Biophys Res Commun. 2015;468:561–7.PubMedCrossRef
17.
Guangzhi L, Gong Y, Bin C, Imelda MU, Miao H, Jingfang Z, Bast RC, Sue-Hwa L, Jinsong L. Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst. 2010;102(11):812–27.CrossRef
18.
Tavare AN, Perry NJS, Benzonana LL, Masao T, Daqing M. Cancer recurrence after surgery: direct and indirect effects of anesthetic agents. Int J Cancer. 2012;130(6):1237–50.PubMedCrossRef
19.
20.
Li X, Peng X, Wang C, Xu N, Xu A, Xu Y, Sadahira T, Araki M, Wada K, Matsuura E. Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma. Oncotarget. 2017;8(13):21177–86.PubMedPubMedCentral
21.
Galimuhtasib HU, Diabassaf M, Haddadin MJ. Retraction note to: Quinoxaline 1,4-dioxides induce G2/M cell cycle arrest and apoptosis in human colon cancer cells. Cancer Chemother Pharmacol. 2018;55(4):369.CrossRef
22.
Thi ND, Hwang ES. Effects of black chokeberry extracts on metastasis and cell-cycle arrest in SK-Hep1 human liver cancer cell line. Asian Pac J Trop Biomed. 2018;8(6):285.CrossRef
23.
Sales MS, Roy A, Antony L, Banu SK, Jeyaraman S, Manikkam R. Octyl gallate and gallic acid isolated from Terminalia bellarica regulates normal cell cycle in human breast cancer cell lines. Biomed Pharmacother. 2018;103:1577.PubMedCrossRef
24.
Liu J, Yang L, Guo X, Jin G, Wang Q, Lv D, Liu J, Chen Q, Song Q, Li B. Sevoflurane suppresses proliferation by upregulating microRNA-203 in breast cancer cells. Mol Med Rep. 2018;18(1):455–60.PubMed
25.
Tangutur AD, Kumar D, Krishna KV, Kantevari S. Microtubule targeting agents as cancer chemotherapeutics: an overview of molecular hybrids as stabilising and destabilising agents. Curr Topics Med Chem. 2017;17(22):2523–37.CrossRef
26.
Li N, Yang L, Deng X, Sun Y. Effects of isoliquiritigenin on ovarian cancer cells. Oncotargets Ther. 2018;11:1633–42.CrossRef
27.
Huang L. Glaucocalyxin A induces G2/M cell cycle arrest and apoptosis through the PI3K/Akt pathway in human bladder cancer cells. Int J Biol Sci. 2018;14(4):418–26.PubMedPubMedCentralCrossRef
28.
Hiroshi Y, Tadashi A, Shun-Ai L, Shota T, Peng H, Masami W, Satoru I, Naohisa O, Akira A, Kohji T. N’-[4-(dipropylamino)benzylidene]-2-hydroxybenzohydrazide is a dynamin GTPase inhibitor that suppresses cancer cell migration and invasion by inhibiting actin polymerization. Biochem Biophys Res Commun. 2014;443(2):511–7.CrossRef
29.
Stegeman H, Span PN, Kaanders JHAM, Bussink J. Improving chemoradiation efficacy by PI3-K/AKT inhibition. Cancer Treat Rev. 2014;40(10):1182–91.PubMedCrossRef
30.
31.
Yang X, Qiang L, Ting L, Zhiping Z, Guanghui W, Dequan Z, Rong D, Cuiling S, Xiao-Kun Z, Haifeng C. U12, a UDCA derivative, acts as an anti-hepatoma drug lead and inhibits the mTOR/S6K1 and cyclin/CDK complex pathways. PLoS ONE. 2014;9(12):e113479.CrossRef
32.
Guo CL, Wang LJ, Zhao Y, Liu H, Li XQ, Jiang B, Luo J, Guo SJ, Wu N, Shi DY. A novel bromophenol derivative BOS-102 induces cell cycle arrest and apoptosis in human A549 lung cancer cells via ROS-mediated PI3K/Akt and the MAPK signaling pathway. Mar Drugs. 2018;16(2):43.PubMedCentralCrossRef
33.
Jenny Szu-Chin P, Luping H, Tatiana B, Lianghao L, Yongjie Y, Roger R, Andy C, Huiming J, Gabriel DM, Qiang T. Stanniocalcin-1 inhibits renal ischemia/reperfusion injury via an AMP-activated protein kinase-dependent pathway. J Am Soc Nephrol. 2015;26(2):364–78.CrossRef
34.
Ohkouchi S, Ono M, Kobayashi M, Hirano T, Tojo Y, Shu H, Ichinose M, Irokawa T, Ogawa H, Kurosawa H. Myriad functions of stanniocalcin-1 (STC1) cover multiple therapeutic targets in the complicated pathogenesis of idiopathic pulmonary fibrosis (IPF). Clin Med Insights Circ Respir Pulm Med. 2015;9(Suppl 1):91–6.PubMedPubMedCentral
35.
Koizumi KHM, Ishida H, Ohyama K, Sugiyama H, Naito A, Toda T, Nakazawa H, Nakazawa S. Stanniocalcin 1 prevents cytosolic Ca2+ overload and cell hypercontracture in cardiomyocytes. Circ J. 2007;71(5):796–801.PubMedCrossRef
36.
Peña C, Céspedes MV, Lindh MB, Kiflemariam S, Mezheyeuski A, Edqvist PH, Hägglöf C, Birgisson H, Bojmar L, Jirström K, Sandström P. STC1 expression by cancer-associated fibroblasts drives metastasis of colorectal cancer. Cancer Res. 2013;73(4):1287–97.PubMedCrossRef
37.
Pan X, Jiang B, Liu J, Ding J, Li Y, Sun R, Peng L, Qin C, Fang S, Li G. STC1 promotes cell apoptosis via NF-κB phospho-P65 Ser536 in cervical cancer cells. Oncotarget. 2017;8(28):46249–61.PubMedPubMedCentral
38.
Leung CC, Wong CK. Effects of STC1 overexpression on tumorigenicity and metabolism of hepatocellular carcinoma. Oncotarget. 2017;9(6):6852–61.PubMedPubMedCentral
39.
Chang CM, Doherty J, Huschtscha LI, Redvers R, Restall C, Reddel RR, Anderson RL. STC1 expression is associated with tumor growth and metastasis in breast cancer. Clin Exp Metastasis. 2015;32(1):15–27.PubMedCrossRef
Metadata
Title
Sevoflurane inhibits the progression of ovarian cancer through down-regulating stanniocalcin 1 (STC1)
Authors
Chuanfeng Zhang
Baosheng Wang
Xiuqin Wang
Xiugui Sheng
Yongchun Cui
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2019
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-019-1062-0

Other articles of this Issue 1/2019

Cancer Cell International 1/2019 Go to the issue

Primary research

Strand-specific miR-28-3p and miR-28-5p have differential effects on nasopharyngeal cancer cells proliferation, apoptosis, migration and invasion

Review

The role of photodynamic therapy on multidrug resistant breast cancer

Primary research

Role of XIAP gene overexpressed bone marrow mesenchymal stem cells in the treatment of cerebral injury in rats with cerebral palsy

Primary research

MiR-566 mediates cell migration and invasion in colon cancer cells by direct targeting of PSKH1

Primary research

Raltitrexed increases radiation sensitivity of esophageal squamous carcinoma cells

Primary research

Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits